التفاصيل البيبلوغرافية
| العنوان: |
Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee. |
| المؤلفون: |
Fung, Maxwell A., Vidal, Claudia I., Armbrecht, Eric A., Andea, Aleodor A., Cassarino, David S., Comfere, Nneka I., Emanuel, Patrick O., Ferringer, Tammie, Hristov, Alexandra C., Jinah Kim, Lauer, Scott R., Linos, Konstantinos, Missall, Tricia A., Motaparthi, Kiran, Novoa, Roberto A., Patel, Rajiv, Shalin, Sara C., Sundram, Uma, Calame, Antoanella, Bennett, Daniel D. |
| المصدر: |
Journal of Cutaneous Pathology; Mar2022, Vol. 49 Issue 3, p231-245, 15p, 1 Diagram, 4 Charts |
| مصطلحات موضوعية: |
REVERSE transcriptase polymerase chain reaction, TELOMERASE reverse transcriptase, DERMATOPATHOLOGY, FLUORESCENCE in situ hybridization, COMPARATIVE genomic hybridization, DIAGNOSIS methods, PSYCHOLOGICAL feedback |
| مصطلحات جغرافية: |
SANTA Monica (Calif.) |
| الشركة/الكيان: |
UNIVERSITY of California, Los Angeles, RAND Corp. |
| مستخلص: |
Background: Appropriate use criteria (AUC) provide patient-centered physician guidance in test selection. An initial set of AUC was reported by the American Society of Dermatopathology (ASDP) in 2018. AUC reflect evidence collected at single timepoints and may be affected by evolving evidence and experience. The objective of this study was to update and expand AUC for selected tests. Methods: RAND/UCLA (RAND Corporation [Santa Monica, CA]/University of California Los Angeles) methodology used includes the following: (a) literature review; (b) review of previously rated tests and previously employed clinical scenarios; (c) selection of previously rated tests for new ratings; (d) development of new clinical scenarios; (e) selection of additional tests; (f) three rating rounds with feedback and group discussion after rounds 1 and 2. Results: For 220 clinical scenarios comprising lymphoproliferative (light chain clonality), melanocytic (comparative genomic hybridization, fluorescence in situ hybridization, reverse transcription polymerase chain reaction, telomerase reverse transcriptase promoter), vascular disorders (MYC), and inflammatory dermatoses (periodic acid-Schiff, Gömöri methenamine silver), consensus by panel raters was reached in 172 of 220 (78%) scenarios, with 103 of 148 (70%) rated "usually appropriate" or "rarely appropriate" and 45 of 148 (30%), "appropriateness uncertain." Limitations: The study design only measures appropriateness. Cost, availability, test comparison, and additional clinical considerations are not measured. The possibility that the findings of this study may be influenced by the inherent biases of the dermatopathologists involved in the study cannot be excluded. Conclusions: AUC are reported for selected diagnostic tests in clinical scenarios that occur in dermatopathology practice. Adhering to AUC may reduce inappropriate test utilization and improve healthcare delivery. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Cutaneous Pathology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |